Table 2.
Studies comparing MDS patients with BMF with those without BMF
| Reference | Patients (N) | Patients with fibrosis, N (%) | OS (months) | AML transformation (%) | DFS |
|---|---|---|---|---|---|
| Wang, et al. 2020 [35] | 157 | 34 (21.7) 24 MF-1 10 MF-2 | 17.7 vs. 47.6; P = 0.001 | 20.3 vs. 41; P = 0.013 | 13.5 vs. 42.0 months, P = 0.002 |
| Fu, et al. 2014 [12] | 630 | MF-2/3 79 (13) Control 166 | 21 vs. 42; P = 0.000 | LFS 52 vs. 120; P = 0.003 | |
| Della Porta, et al. 2009 [10] | 298 | MF-1 128 (43) MF-2 45 (15) MF-3 7 (2) | Inferior in 2/3 vs. 0/1; P < 0.0001 | Inferior in 2/3 vs. 0/1; P < 0.0001 | |
| Maschek, et al. 1992 [32] | 352 | 61 (17.3) | 10 vs. 28.9 | 36.6 in patients with BMF | |
| Marisavljević, et al. 2004 [27] | 236 | 126 (53.4) | 13 vs. 35; P = 0.00055 | 24.1 vs. 18.9 | |
| Melody, et al. 2020 [25] | 2,624 | MF-0–2 2,517 MF-3 107 | 19 vs. 56; P = 0.02 (alloSCT) | 29 vs. 28; P = 0.84 |
Abbreviations: MDS, myelodysplastic syndrome; BMF, bone marrow fibrosis; OS, overall survival; AML, acute myeloid leukemia; DFS, disease-free survival; MF-1/2/3, BMF grade 1/2/3; LFS, leukemia-free survival; MF, myelofibrosis; alloSCT, allogeneic stem cell transplantation.